Ro5
The AI engine Fit Assessment
BetaRo5 leverages machine learning to enhance drug discovery, identify patterns, and expand therapeutic options, including drug repurposing efforts for COVID-19.
Blurb
HQ Location
Founded
Employees
Total funding raised
Last Funding Event
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
- Drug Repurposing
Developer of healthcare platform designed to revolutionize drug discovery and delivery process. The company's artificial intelligence and machine learning-based platform feature drug identification, curated database, bioactivity tool, visualization and analytics system and clinical trial analytics that help to speed up drug improvement, development, repurposing and clinical trials, enabling clients to reduce discovery time, increase accuracy, boost clinical trial success and lower costs exponentially.